Fulgent Genetics

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fulgent Genetics surpasses revenue targets, eyes precision medicine growth

Fulgent Genetics delivered strong financial performance in 2022, exceeding revenue guidance and positioning for continued growth in 2023 across key business segments.
The company's strategic focus on precision medicine, oncology, and pharma services, coupled with a robust cash position, sets the stage for future expansion and innovation.
Challenges in margin improvement and reimbursement highlight areas for operational refinement, while opportunities in acquisitions and menu expansion offer avenues for sustained growth.

Fulgent Genetics reports robust Q1 revenue growth and strategic advancements

Fulgent Genetics delivered strong revenue growth in Q1 2023, with a focus on core business strength and promising developments in key drug candidates and business segments.
While facing challenges in operational efficiency and negative Adjusted EBITDA, the company maintains a strong cash position and is optimistic about future opportunities.
Strategic acquisitions, market expansion, and continued margin improvement are key areas of focus for Fulgent Genetics to drive sustained growth and profitability.

Fulgent Genetics reports record Q2 revenue and advances in cancer treatment

Fulgent Genetics (FLGT) delivered a strong performance in Q2 2023, with record core revenue and promising developments in cancer treatment.
The company's focus on innovation, operational efficiency, and margin improvement underscores a commitment to sustainable growth.
While facing challenges in cost management and competitive dynamics, Fulgent Genetics is well-positioned to capitalize on opportunities through technology and strategic initiatives.

Fulgent Genetics reports robust Q3 earnings, eyes growth in precision diagnostics

Fulgent Genetics demonstrated solid financial performance in Q3 2023, with strong core revenue and improved gross margins. The company continues to focus on precision diagnostics and therapeutic development, presenting growth opportunities. Challenges include fluctuations in Pharma services revenue and COVID-19 testing demand.

Fulgent Genetics surpasses Q4 revenue targets, eyes FDA regulatory landscape

Fulgent Genetics delivered strong Q4 results, exceeding revenue guidance and showcasing growth in core revenue.
The company faces challenges in BioPharma Services and Anatomic Pathology but is investing in operations and AI for improvement.
Opportunities lie in Precision Diagnostics growth, market share gains in carrier screening, and adapting to FDA oversight of laboratory developed tests.
Management's confidence in quality systems and readiness to pursue FDA approval for high-risk tests position Fulgent Genetics for regulatory changes.

Fulgent Genetics excels in Q1 2024 with strong revenue growth

Fulgent Genetics delivered strong Q1 results driven by precision diagnostics and therapeutic development progress.
While facing challenges in managing expenses, the company showcased financial discipline and innovation in new product launches.
With a focus on improving margins and capturing market opportunities, Fulgent Genetics aims for continued growth and profitability in 2024.

Fulgent Genetics reports robust Q2 revenue, invests in innovative treatments

Fulgent Genetics demonstrated solid revenue performance in Q2, driven by core business growth in key segments.
While facing profitability challenges, the company continues to invest in innovative treatments and technology.
Maintaining a strong cash position and focusing on strategic growth areas position Fulgent Genetics for future success.
Balancing cost management with revenue growth will be crucial for the company's financial health and long-term sustainability.

Fulgent Genetics reports robust Q3 earnings, eyes strategic growth opportunities

Fulgent Genetics demonstrated solid revenue growth and financial stability in Q3 2024.
The company's focus on precision diagnostics and therapeutic development shows promise for future growth.
Challenges lie in maintaining margins, managing expenses, and optimizing the VA contract's impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

Adaptive Biotechnologies

NRX Pharmaceuticals

Want a two-bagger this year? These three COVID stocks just might do it.

3 COVID Stocks That Could Double in 2022

FedEx

These stocks are both trading at less than 15 times their earnings.

2 Cheap Growth Stocks to Buy for 2022

Avis Budget Group

Signet Jewelers

Avis Budget Group (CAR), Signet Jewelers (SIG) and Fulgent Genetics (FLGT) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.

Buy These 3 Stocks With Momentum Anomaly for Higher Returns

Moderna

The pandemic may have brought these companies to prominence, but there's much more to the story.

My 2 Favorite Healthcare Stocks for 2022

Armada Hoffler Properties

JOANN

Murphy USA

MUSA, JOAN, FLGT, and AHH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 28, 2021.

Best Momentum Stocks to Buy for December 28th

Fulgent's COVID testing business isn't going away any time soon and will continue to gush cash for reinvestment, even allowing for melting ice cube scenarios.

Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Fullgent Genetics (FLGT) Crossed Above the 50-Day Moving Average: What That Means for Investors

Axcelis Technologies

Berry Global Group

Guild Holdings

ACLS, FLGT, GHLD, and BERY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 8, 2021.

Best Momentum Stocks to Buy for December 8th

Shares fell earlier in the November, but popped again after a robust third-quarter earnings report.

Is Fulgent Genetics a Good Healthcare Stock to Buy?

IRVINE & TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Helio Health (“Helio”) and its commercial partner, Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), today announced the commercial launch of HelioLiver™, a multi-analyte blood test that incorporates cell free DNA (cfDNA) methylation patterns and serum protein markers for the detection of hepatocellular carcinoma (HCC) – the most common form of liver cancer. HelioLiver can detect HCC at its earliest stages when lesions are still very small, an are

HelioLiver™, an Innovative Liquid Biopsy Test for the Early Detection of Liver Cancer, is Now Commercially Available

The genetic testing company's moat is expanding.

How Wide Is Fulgent Genetics' Moat?

AbbVie

Teladoc

Shares of these companies are gift-wrapped for those with patience.

3 Stocks That Could Make You Richer in December (and Beyond)

TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today confirmed that the Company's RT-PCR test for SARS-CoV-2, the virus that causes COVID-19, can successfully detect the recently emerged Omicron variant of the virus. In addition, Fulgent is confident that its Next Generation Sequencing (NGS)

Fulgent Genetics Confirms Ability to Detect Omicron Variant with RT-PCR Tests for COVID-19

Whether Fulgent is a value or a value trap depends on the short-term prospects for COVID-19 and the long-term prospects for its core sequencing business.

Is Fulgent Genetics Undervalued?

Ocugen, Inc.

Beyond Air Inc

Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics.

3 Small-Cap COVID Stocks With Huge Upside

Fulgent's recent earnings report confirmed the strength of its core testing business.

The Monster Business Lurking Behind Fulgent's COVID Results

How Is Fulgent Genetics Staying Ahead of Its Competition?

Fullgent Genetics (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Fullgent Genetics (FLGT) Stock

Ameresco

Alpha and Omega Semiconductor

Saia

AOSL, FLGT, AMRC, and SAIA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 19, 2021.

Best Momentum Stocks to Buy for November 19th

Lazydays

Matson

Schnitzer Steel Industries

AOSL, FLGT, LAZY, MATX, and SCHN have been added to the Zacks Rank #1 (Strong Buy) List on November 19, 2021.

New Strong Buy Stocks for November 19th

The genetic testing company delivered a solid performance in Q3.

What Investors Should Like About Fulgent Genetics' Q3 Results

Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

Fullgent Genetics (FLGT) Crossed Above the 200-Day Moving Average: What That Means for Investors

Investors worry about the demise of their insanely profitable Covid business, but they shouldn't. The epic ramp in that business put the company on the map and will deliver $1B+ in cash by the end of the year.

Fulgent Shares Are Still Very Attractive

Fulgent Genetics Inc (NASDAQ: FLGT) reported Q3 sales of $227.9 million, +124% Y/Y, beating the consensus of $264 million primarily driven by sales of its COVID-19 tests. Fulgent said that the billable tests delivered in the quarter grew to approximately 2.2 million, up from 1.04 million in Q3 2020.

Fulgent Genetics Q3 Revenues More Than Double; Raises FY21 Outlook

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q3 2021 Results - Earnings Call Transcript

News for Fulgent Genetics Stock (FLGT)